ANALISIS DRPs STATIN DAN ESTIMASI RISIKO ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) PASIEN DIABETES MELITUS TIPE 2 RAWAT JALAN DI RS “X” SAMARINDA
Abstrak
Atherosclerotic Cardiovascular Disease (ASCVD) is the main cause of death in patients with diabetes mellitus with a cardiovascular risk that will increase 2-4 times higher than non-diabetic patients. The statin group is a class of drugs recommended by ACC/AHA 2018 in reducing cardiovascular risk in patients with type 2 diabetes mellitus. This study aims to analyze Drug Related Problems (DRPs) of statin drugs in patients with type 2 diabetes mellitus and calculate the estimated risk for the next 10 years. The research was conducted using a non-experimental descriptive analytic method. Data collection was carried out retrospectively through a population of 194 type 2 diabetes mellitus patients at "X" Samarinda Hospital for the period January-September 2022, 11 patient medical record data were obtained through the Total Sampling technique whose sampling complied with the inclusion and exclusion criteria. The results showed that the most commonly prescribed statins were simvastatin 20 mg in 9 patients (82%), and atorvastatin 20 mg in 2 patients (18%). The results of the DRPs analysis showed that there were 4 cases of DRPs consisting of 1 case of underdose (25%), and 3 cases of drugs not being indicated for the existing medical profile (75%). The total risk level of ASCVD based on the calculation of the ASCVD calculator found that 3 patients (27%) had low risk, 4 patients (36%) medium risk, and 4 patients (36%) high risk.
Referensi
Bideberi, A. T., & Mutagaywa, R. (2022). Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania [Response to Letter]. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15(January), 1111–1112. https://doi.org/10.2147/DMSO.S368402
Demoz GT, Wahdey S, Kasahun GG, et al. (2019). Prescribing Pattern of Statins for Primary Prevention of Cardiovascular Diseases in Patients With Type 2 Diabetes: Insights From Ethiopia. BMC Res Notes, 12(1), 386. https://doi.org/10.1186/s13104-019-4423-9
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., De Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., … Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. In Circulation (Vol. 139, Issue 25). https://doi.org/10.1161/CIR.0000000000000625
International Diabetes Federation (IDF), (2021). International Diabetic Federation. In Diabetic Atlas (10th ed.).
Mwita JC, Godman B, E. T. (2020). Statin Prescription Among Patients With Type 2 Diabetes in Botswana: Findings and Implications. BMC Endocr Disord, 20(1), 36. https://doi.org/10.1186/s12902-020-0516-7
Nasution, Fitriani., A. A. A. S. (2021). Faktor Risiko Kejadian Diabetes Melitus. Jurnal Ilmu Kesehatan, 9(2), 94–102.
PERKENI, (2021). Pedoman Pengelolaan Dislipidemia di Indonesia. Pengurus Besar Perkumpulan Endokrinologi Indonesia (PB PERKENI).
Putri, I. S., Brahmantya, I. B. Y., Dwipayana, I. M. P., Made, Saraswati, R., & Wirawan, I. M. A. (2020). Gambaran tingkat risiko penyakit kardiovaskular pada pasien diabetes melitus tipe 2 di puskesmas kota denpasar. Jurnal Medika Udayana, 9(11), 62–67.
Riskesdas. (2018). Hasil Utama Riskedas 2018. Kemenkes.
World Health Organization (WHO). (2021). Cardiovascular Diseases (CVDs).
World Health Organization (WHO). (2022). Global Report On Diabetes. World Health Organization. http://www.who.int/iris/handle/10665/20487.
Widyati. (2019). Praktik Farmasi Klinik: Fokus Pada Pharmaceutical Care (I). Uwais Inspirasi Indonesia.
##submission.copyrightStatement##
##submission.license.cc.by-nc4.footer##
